Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study

1. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 4115–27. doi: 10.3748/wjg.v20.i15.4115 RazaA SoodGK Hepatocellular carcinoma review: current treatment, and evidence-based medicine World J Gastroenterol 2014 20 4115 27 10.3748/wjg.v20.i15.4115 Open DOISearch in Google Scholar

2. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; CD004787. doi: 10.1002/14651858.CD004787.pub2 OliveriRS WetterslevJ GluudC Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma Cochrane Database Syst Rev 2011 CD004787 10.1002/14651858.CD004787.pub2 Open DOISearch in Google Scholar

3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90. doi: 10.1056/NEJMoa0708857 LlovetJM RicciS MazzaferroV HilgardP GaneE BlancJF Sorafenib in advanced hepatocellular carcinoma N Engl J Med 2008 359 378 90 10.1056/NEJMoa0708857 Open DOISearch in Google Scholar

4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34. doi: 10.1016/s1470-2045(08)70285-7 ChengAL KangYK ChenZ TsaoCJ QinS KimJS Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 2009 10 25 34 10.1016/s1470-2045(08)70285-7 Open DOISearch in Google Scholar

5. Li Q, Su T, Zhang X, Pan Y, Ma S, Zhang L, et al. A real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma. Cancer Manag Res 2022; 14: 3037–46. doi: 10.2147/cmar.S379911 LiQ SuT ZhangX PanY MaS ZhangL A real-world study of optimal treatment with anlotinib first-line therapy in advanced hepatocellular carcinoma Cancer Manag Res 2022 14 3037 46 10.2147/cmar.S379911 Open DOISearch in Google Scholar

6. Chen XQ, Zhao YX, Zhang CL, Wang XT, Zhang X, Chen X, et al. Effectiveness and safety of anlotinib with or without PD-1 blockades in the treatment of patients with advanced primary hepatocellular carcinoma: a retrospective, real-world study in china. Drug Des Devel Ther 2022; 16: 1483–93. doi: 10.2147/dddt.S358092 ChenXQ ZhaoYX ZhangCL WangXT ZhangX ChenX Effectiveness and safety of anlotinib with or without PD-1 blockades in the treatment of patients with advanced primary hepatocellular carcinoma: a retrospective, real-world study in china Drug Des Devel Ther 2022 16 1483 93 10.2147/dddt.S358092 Open DOISearch in Google Scholar

7. Murer F, Pozzan C, Peserico G, Farinati F. Capecitabine in advanced hepatocellular carcinoma. Dig Liver Dis 2016; 48: 1260–1. doi: 10.1016/j.dld.2016.06.037 MurerF PozzanC PesericoG FarinatiF Capecitabine in advanced hepatocellular carcinoma Dig Liver Dis 2016 48 1260 1 10.1016/j.dld.2016.06.037 Open DOISearch in Google Scholar

8. Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018; 144: 403–14. doi: 10.1007/s00432-017-2556-6 TrevisaniF BrandiG GarutiF BarberaMA TortoraR Casadei GardiniA Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation J Cancer Res Clin Oncol 2018 144 403 14 10.1007/s00432-017-2556-6 Open DOISearch in Google Scholar

9. Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 2017; 7: 42499. doi: 10.1038/srep42499 Casadei GardiniA FocaF ScartozziM SilvestrisN TamburiniE FaloppiL Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study Sci Rep 2017 7 42499 10.1038/srep42499 Open DOISearch in Google Scholar

10. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329–38. doi: 10.1055/s-2007-1007122 LlovetJM BrúC BruixJ Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 1999 19 329 38 10.1055/s-2007-1007122 Open DOISearch in Google Scholar

11. Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 2020; 20: 1001–14. doi: 10.3892/ol.2020.11685 GaoY LiuP ShiR Anlotinib as a molecular targeted therapy for tumors Oncol Lett 2020 20 1001 14 10.3892/ol.2020.11685 Open DOISearch in Google Scholar

12. Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res 2019; 38: 71. doi: 10.1186/s13046-019-1093-3 LiangL HuiK HuC WenY YangS ZhuP Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells J Exp Clin Cancer Res 2019 38 71 10.1186/s13046-019-1093-3 Open DOISearch in Google Scholar

13. Tang X, Zheng Y, Jiao D, Chen J, Liu X, Xiong S, et al. Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-MET pathway and activation of ERK1/2 pathway in H446 cells. Anticancer Agents Med Chem 2021; 21: 747–55. doi: 10.2174/1871520620666200718235748 TangX ZhengY JiaoD ChenJ LiuX XiongS Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-MET pathway and activation of ERK1/2 pathway in H446 cells Anticancer Agents Med Chem 2021 21 747 55 10.2174/1871520620666200718235748 Open DOISearch in Google Scholar

14. Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19: 1338–50. doi: 10.1016/s1470-2045(18)30495-9 FangW YangY MaY HongS LinL HeX Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials Lancet Oncol 2018 19 1338 50 10.1016/s1470-2045(18)30495-9 Open DOISearch in Google Scholar

15. Lan W, Zhao J, Chen W, Shang H, Peng J, Lin J. Anlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K/AKT pathway. Anticancer Agents Med Chem 2021; 21: 1987–95. doi: 10.2174/1871520621666210112113852 LanW ZhaoJ ChenW ShangH PengJ LinJ Anlotinib overcomes multiple drug resistant colorectal cancer cells via inactivating PI3K/AKT pathway Anticancer Agents Med Chem 2021 21 1987 95 10.2174/1871520621666210112113852 Open DOISearch in Google Scholar

16. Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med 2018; 7: 4570–83. doi: 10.1002/cam4.1664 YangC QinS Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma Cancer Med 2018 7 4570 83 10.1002/cam4.1664 Open DOISearch in Google Scholar

17. Zhen L, Jiali C, Yong F, Han X, Hongming P, Weidong H. The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study. J Cancer 2018; 9: 2773–7. doi: 10.7150/jca.26376 ZhenL JialiC YongF HanX HongmingP WeidongH The efficacy and safety of apatinib treatment for patients with unresectable or relapsed liver cancer: a retrospective study J Cancer 2018 9 2773 7 10.7150/jca.26376 Open DOISearch in Google Scholar

18. Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, et al. Anlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with PS scores of 2–3 after progression of second-line or later-line treatment. Cancer Manag Res 2020; 12: 12709–14. doi: 10.2147/cmar.S278068 XieXH WangF LinXQ QinYY XieZH ZhangJX Anlotinib plus S-1 for patients with EGFR mutation-negative advanced squamous cell lung cancer with PS scores of 2–3 after progression of second-line or later-line treatment Cancer Manag Res 2020 12 12709 14 10.2147/cmar.S278068 Open DOISearch in Google Scholar

19. Xiang M, Yang X, Ren S, Du H, Geng L, Yuan L, et al. Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial. Oncologist 2021; 26: e2130–e5. doi: 10.1002/onco.13950 XiangM YangX RenS DuH GengL YuanL Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial Oncologist 2021 26 e2130 e5 10.1002/onco.13950 Open DOISearch in Google Scholar

20. Yang X, Xiang M, Geng L, Wen Y, Du X. Anlotinib combined with S-1 in the third-line treatment of stage IV non-small cell lung cancer: study protocol for phase II clinical trial. Asian Pac J Cancer Prev 2019; 20: 3849–53. doi: 10.31557/apjcp.2019.20.12.3849 YangX XiangM GengL WenY DuX Anlotinib combined with S-1 in the third-line treatment of stage IV non-small cell lung cancer: study protocol for phase II clinical trial Asian Pac J Cancer Prev 2019 20 3849 53 10.31557/apjcp.2019.20.12.3849 Open DOISearch in Google Scholar

21. Song D, Song M, Bae S, Chung W, Jang J, Kim Y, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol 2015; 50: 445–54. doi: 10.1007/s00535-014-0978-3 SongD SongM BaeS ChungW JangJ KimY A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis J Gastroenterol 2015 50 445 54 10.1007/s00535-014-0978-3 Open DOISearch in Google Scholar

22. Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun 2019; 39: 36. doi: 10.1186/s40880-019-0383-7 ZhouM ChenX ZhangH XiaL TongX ZouL China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy Cancer Commun 2019 39 36 10.1186/s40880-019-0383-7 Open DOISearch in Google Scholar

23. Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thorac Cancer 2019; 10: 551–6. doi: 10.1111/1759-7714.12977 SiX ZhangL WangH ZhangX WangM HanB Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303 Thorac Cancer 2019 10 551 6 10.1111/1759-7714.12977 Open DOISearch in Google Scholar

24. Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, et al. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021; 15: 621–9. doi: 10.1007/s12072-021-10171-0 SunY ZhouA ZhangW JiangZ ChenB ZhaoJ Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study) Hepatol Int 2021 15 621 9 10.1007/s12072-021-10171-0 Open DOISearch in Google Scholar